N-glycosylation is required for efficient secretion of a novel human secreted glycoprotein, hPAP21  by Zhou, Yu-Bo et al.
FEBS 28871 FEBS Letters 576 (2004) 401–407N-glycosylation is required for eﬃcient secretion of a novel
human secreted glycoprotein, hPAP21Yu-Bo Zhoua,b, Feng Liub, Zhi-Dong Zhub, Hong Zhub, Xin Zhangb, Zhi-Qin Wangb,
Jian-Hua Liua, Ze-Guang Hanb,*
aCollege of Life Science and Biotechnology, Shanghai Jiaotong University, 1954 Huashan Road, Shanghai 200030, China
bChinese National Human Genome Center at Shanghai, 351 Guo Shou-Jing Road, Shanghai 201203, China
Received 5 July 2004; revised 10 September 2004; accepted 14 September 2004
Available online 25 September 2004
Edited by Takashi GojoboriAbstract The present study reported the isolation and charac-
terization of a novel human secreted protein, named as hPAP21
(human protease-associated domain-containing protein, 21 kDa),
encoded by the hypothetical gene chromosome 2 open reading
frame 7 (C2orf7) that contains signal peptide in its N-terminus,
without transmembrane domain, except for PA domain in its
middle. Western blotting assay indicated that the c-Myc tagged
hPAP21 could be secreted into culture medium in the transfected
Chinese hamster ovary cells. However, the molecular weights,
whatever intracellular (28 kDa) or extracellular (30 kDa) forms,
are larger than that of the prediction. To deﬁne whether the
glycosylation was important process for its secretion, endogly-
cosidase H (Endo H) and PNGase F (PNG F) were employed to
evaluate the eﬀect of glycosylation types on secretion of
hPAP21. Interestingly, the extracellular forms were primarily
sensitive to PNG F, not Endo H, implying that complex
N-glycosylation could be required for the secretion of hPAP21.
Furthermore, N-glycosylation of Asn171 was conﬁrmed as
potential crucial process for the secretory protein via site-
directed mutagenesis assay. All data will be contributed to the
understanding of molecular functions of hPAP21.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
Keywords: Human protease-associated domain-containing
protein, 21 kDa; Chromosome 2 open reading frame 7;
Glycosylation; Secretion1. Introduction
About 10% of the whole human proteins, including cyto-
kines, hormones, digestive enzymes, and immunoglobulins, are
secretory proteins [1]. These proteins play important roles in
many fundamental cellular and organism functions, such as
immune defense, intercellular communication, morphogenesis,
angiogenesis, apoptosis, and cell diﬀerentiation [2]. Moreover,* Corresponding author. Fax: +86-21-50800402.
E-mail address: hanzg@chgc.sh.cn (Z.-G. Han).
Abbreviations: C2orf7, chromosome 2 open reading frame 7; RT-PCR,
reverse transcription-polymerase chain reaction; PBS, phosphate-
buﬀered saline; PAGE, polyacrylamide gel electrophoresis; CHO,
Chinese hamster ovary; Endo H, endoglycosidase H; PNG F, PNGase
F; ER, endoplasmic reticulum; TGN, trans-Golgi network; aa, amino
acid; CL, cell lysate; CM, culture medium
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doi:10.1016/j.febslet.2004.09.039human tissue-speciﬁc plasminogen activators, erythropoietins,
peptide hormones and digestive enzymes account for the large
majority of protein therapeutics [3].
Post-translational modiﬁcations are common in eukaryotic
secreted proteins. The most common and complex post-
translational modiﬁcation is glycosylation that could be rele-
vant to about 1% of genes in the mammalian genome although
there are 20 post-translational modiﬁcations in eukaryotic cells
[4–6]. Glycosylation appears to be very conserved from yeast
to humans, and more, over half of the glycosylated proteins
are reported to have N-linked oligosaccharides. The N-linked
glycosylations could facilitate protein folding, protect proteins
from proteolysis, and guide protein traﬃcking; meanwhile, the
glycans of secreted proteins are important for secretion [7–12].
Apparently, identiﬁcation for the genes encoding secreted
proteins will be very signiﬁcant, not only for understanding
their roles in biological processes, but also for the potential
applications in therapeutics. Recently, we performed a strategy
to predict potentially secreted proteins based on bioinformat-
ics tools and human genomic information, and then the pre-
dicted genes were isolated and characterized through further
experiments [13]. In this study, a novel human protease-asso-
ciated domain-containing protein, 21 kDa (hPAP21), encoded
by the hypothetical gene chromosome 2 open reading frame 7
(C2orf7), was also screened out as a candidate that was con-
ﬁrmed to be secreted into culture medium (CM) in vitro, and
N-glycosylation could be important to its secretion.2. Materials and methods
2.1. Bioinformatics analysis
Bioinformatic prediction was performed as described previously [13]
by using softwares, including SignalP v.2.0 (http://www.cbs.dtu.dk/
services/SignalP-2.0/), PSORT II (http://psort.nibb.ac.jp/) and SOSUI
(http://sosui.proteome.bio.tuat.ac.jp/sosuiframe0.html), which were
used for predicting signal peptide, subcellular localization, hydropho-
bicity and transmembrane region, respectively. The homologous anal-
yses of the candidate secretory proteins were carried out via BLAST
(http://www.ncbi.nlm.nih.gov/BLAST/) programs, while modiﬁcation
sites of proteins were predicted through PROSITE (http://us.exp-
asy.org/prosite/). Multiple sequence alignment and phylogenic analysis
were performed using ClustalW and MEGA2 programs.
2.2. RNA extraction and RT-PCR
Total RNA was extracted with TRIzol reagent (Life Technologies
Inc., Gaithersburg, MD) according to the protocol recommended by
the manufacturer. Reverse transcription was carried out at 42 C foration of European Biochemical Societies.
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10 pmol of oligo(dT), and 200 unit of M-MLV Reverse Transcriptase
(Promega, Madison, USA). The entire open reading frame (ORF) of
C2orf7 was ampliﬁed by polymerase chain reaction (PCR) with the
designed primers. PCR mixture was preheated at 94 C for 4 min, and
then thermal-cycled for 35 cycles (94 C for 40 s, 60 C for 30 s, and
72 C for 50 s), and ended with a ﬁnal extension at 72 C for 7 min.
2.3. Expression vector construction
Wild-type hPAP21 with entire ORF was inserted into mammalian
expression vector pcDNA3.1-Myc-HisA ()) vector (Invitrogen, San
Diego, CA) through amplifying DNA fragment using PCR, in order
to generate the hPAP21-Myc fusion protein with c-Myc tag at the
C-terminus. Site-directed mutagenesis was used to generate the mu-
tated proteins (Fig. 1A) based on PCR method [14]. In brief, the
consensus sequence of glycosylation, Asn-Xaa-Ser/Thr, was mutated
by creating codons for Gln (CAA) instead of Asn (AAT). Wild-type
and mutants’ primers were the following (underline indicated the
mutated sites): forward primer for wild-type (W-F-P): 50-CCGGAT-
CCATGGTCCCCGGCGC-30; reverse primer for wild-type (W-R-P):
50-CCAAGCTTCCAGAAGGTCCAGGGC-30; forward primer for
mutant 1(Asn121Gln) (M-1-F-P): 50-GACAACGCAGTTGACCAA-
GACAGCTTCTACG-30; reverse primer for mutant 1 (M-1-R-P):
50-CGTAGAAGCTGTCTTGGTCAACTGCGTTGTC-30; reverse
primer for mutant 2(Asn171Gln)(M-2-R-P): 50-CCAAGCTTCCAGA-
AGGTCCAGGGCGGTTGCAGCAGCTCAAAGGTGGGGATGC
TGGTGACTTGGACTGGGATGGAAATGATGGCCC-30. Two
DNA fragments were ampliﬁed, one by the paired primers M-1-F-P
and W-R-P, as well as the other by W-F-P and M-1-R-P, which wild-
type hPAP21 was used as template. The PCR products were puriﬁed
with MiniEluteTM Gel Extraction Kit (Qiagen GmbH, Hilden, Ger-
many), respectively, and then mixed as template for the second PCR
through the primers W-F-P and W-R-P. The puriﬁed PCR product
was inserted into pcDNA3.1-Myc-HisA ()) vector to generate a re-
combinant plasmid pcDNA3.1A-hPAP21-mutant 1-Myc. Similarly,
recombinant plasmid pcDNA3.1A-hPAP21-mutant 2-Myc also was
generated using W-F-P and M-2-R-P primers, which wild-type
hPAP21 was used as template. The recombinant plasmid containing
mutant 3 (Asn121Gln and Asn171Gln) with both mutated sites was
constructed by PCR with primers W-F-P and M-2-R-P, which vector
pcDNA3.1A-hPAP21-mutant 1-Myc was used as template. The PCR
condition was done as above and products were analyzed by electro-
phoresis on a 2% agarose gel. All constructs were conﬁrmed by DNA
sequencing.
2.4. Northern blot analysis
Human Multiple Tissue Northern Blot (Clontech, Polo Alto, CA)
membrane was hybridized according to the manufacturer’s protocol,
which partial hPAP21 (60–564 nt) PCR product was used as probe
that was 32P-labeled with Random Primer DNA Labeling KitFig. 1. The representative structure of the hPAP21 (C2orf7). (A)
Schematic structure of wild-type hPAP21 and its mutants. SP, signal
peptide; PA domain, protease-associated domain. Asterisks indicate
the potential N-glycosylation sites; triangles indicate Asn residues
mutated to Gln. The numbers below the schematic structure indicate
the length of the protein. (B) Schematic genomic structure of the
hPAP21 (C2orf7). Black boxes represent exons, while horizontal lines
represent introns.(TaKaRa Inc, DaLian, China). After hybridization, the membrane
was washed in 2 sodium saline citrate (SSC), 0.05% sodium dodecyl
sulfate (SDS) at room temperature for 3· (30 min each time), and then
in 0.1 sodium saline citrate (SSC), 0.1% SDS for 2 times (30 minutes
each time) at 50 C, and ﬁnally visualized by autoradiography.
2.5. Cell transfection and selection of stably transfected cells
The recombinant plasmids containing wild-type hPAP21 or mu-
tants were transiently transfected into Chinese hamster ovary (CHO)
cells (1.5 105 cells/35 mm dish) with LipofectAMINE reagents
(Gibco-BRL), respectively, according to the manufacturer’s protocol.
The CHO cells were cultured and grown overnight in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Gibco-BRL, Gaithersburg,
MD) supplemented with 10% (v/v) fetal bovine serum (FBS) by 5%
CO2 at 37 C. For selection of stably transfected subclones, G418
(1.0 mg/ml) (Life Technologies) was supplemented for 3 days after
cell transfection, and then the cells were continuously cultured in
10% FBS/DMEM for 3 weeks. The subclones were selected, ex-
panded and detected by Western blotting with antibody 9E10
(Clontech) against c-Myc tag.
2.6. Western blot analysis
After the CM of CHO cells transfected with recombinant plasmids
was collected, the remaining cells were washed with cold phosphate-
buﬀered saline (PBS) (pH 7.4) two times (5 min each time) and lysed
with lysis buﬀer (50 mmol/L Tris–HCl, pH 8.0, 150 mmol/L NaCl,
100 lg/ml PMSF, and 1% Triton-X 100) on ice for 30 min. The CM
and the cell lysates (CL) were puriﬁed using TALON metal aﬃnity
resins (Clontech) according to the manufacturer’s manual. Puriﬁed
proteins were separated by 15% SDS–polyacrylamide gel electro-
phoresis (PAGE) and electro-transferred onto a PVDF membrane
(Amersham Pharmacia Biotech AB, Uppsala, Sweden). After being
blocked by PBS containing 2% bovine serum albumin (BSA), 3%
non-fat milk and 0.1% Tween 20 overnight at 4 C, the membrane
was incubated with monoclonal antibody against human c-Myc
(9E10) (Clontech) (1:1000 dilution) at room temperature for 2 h, and
followed by incubation with a horseradish peroxidase-linked goat
anti-mouse secondary antibody (Gibco-BRL) (1:10 000 dilution) at
room temperature for 2 h. The signals were detected with the en-
hanced chemiluminescence detection system (ECL, Amersham
Pharmacia Biotech).
2.7. Subcellular localization
Cells cultured on polylysine-treated slides were co-transfected with
2 lg of plasmids pcDNA3.1-hPAP21-Myc and pEYFP-Golgi (Clon-
tech) using LipofectAMINE (Gibco BRL). After 60 h, the transfected
cells were washed 2· PBS and ﬁxed with 4% paraformaldehyde/
0.1%Triton-X 100 in PBS on ice for 30 min. The cells were immuno-
stained with monoclonal antibody to c-Myc (9E10) (Clontech) (1:200
dilution) at room temperature for 2 h after being blocked in PBS
containing 5% BSA overnight at 4 C, and followed by incubation with
goat anti-mouse antibody–Cy5 conjugate (Biological Detection Sys-
tems, Inc, Pittsburgh, PA, USA) (1:400 dilution) at room temperature
for 2 h. The slides were viewed by confocal scanning microscopy (Leica
Microsystems Heidelberg GmbH, Germany).2.8. Deglycosylation experiments
The puriﬁed proteins from CL or CM were pre-denatured in 1
Glycoprotein Denaturing Buﬀer at 100 C for 10 minutes. According
to the manufacturer’s instructions, the denatured proteins were treated
with PNGase F (PNG F) (New England Biolabs Inc, Beverly, MA,
USA) or Endo H (New England Biolabs), respectively, at 37 C
overnight. The digested proteins were analyzed by Western blotting
assay after separated on 15% SDS–PAGE.
2.9. Tunicamycin treatment
The stable transfected cell line with exogenous hPAP21 and its
variants was seeded at 5 105/35-mm dish and cultured for 24 h, and
then the medium was replaced with fresh medium containing tu-
nicamycin (Sigma, St. Louis, MO) (2.0 lg/ml) or the same volume of
dimethyl sulfoxide and cultured for additional 24 h. The proteins
puriﬁed from CL and CM were analyzed with Western blotting
assay.
Y.-B. Zhou et al. / FEBS Letters 576 (2004) 401–407 4033. Results
3.1. Isolation and characterization of hPAP21
hPAP21, encoded by the hypothetical geneC2orf7 (GenBank
Accession No. NM 032319), was screened out as potential se-Fig. 2. Phylogenetic relationship between hPAP21 and some associated protei
Identical residues are in black and conserved substitutions are in gray. The
logenetic tree of hPAP21 and its orthologs. mPAP21, mouse PAP21 (XP_13
PAP21, Anopheles gambiae PAP21 (XP_314522); XlPAP21, Xenopus laev
(CAE68661); CePAP21, C. elegans PAP21 (NP_l508831).cretory protein using the previous strategy [13]. Analyses of
SignalP and SOSUI softwares implied that the hPAP21 protein
has a signiﬁcant signal peptide in its N-terminus (aa: 1–20)
(Fig. 1A), without transmembrane regions. Furthermore, the
possibility of extracellular localization is 66.7%, much higherns. (A) Multiple aa sequence alignment of hPAP21 and some homologs.
numbers of right side represent the length of each sequence. (B) Phy-
2652); DmPAP21, Drosophila melanogaster PAP21 (NP_611740); Ag-
is PAP21 (AAH70658); CbPAP21, Caenorhabditis briggsae PAP21
Fig. 4. The analyses of glycosylation type of intracellular and extra-
cellular hPAP21. Protein was harvested from CL and CM that derived
from stably transfected CHO cells with exogenous hPAP21, and then
digested with PNG F and Endo H, respectively, after puriﬁcation by
TALON metal aﬃnity resins. ‘‘a–c’’ arrows indicate the diﬀerent bands
with distinct sizes from CL and CM with (+) or without ()) enzymes
treatment (PNG F; Endo H).
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which hPAP21 were predicted by the PSORT II program. All
the computational predictions suggested that the hypothetical
gene hPAP21 (C2orf7) might encode a secretory protein albeit
the hypothesis needs to be conﬁrmed.
hPAP21 (C2orf7) has ﬁve exons and four introns, spanning
5244 bp in human genome context (Fig. 1B) although hPAP21
only encodes 188 amino acid (aa) residues with a PA domain
(Fig. 1A). Interestingly, hPAP21 might have its orthologs from
worm to mouse, sharing 41–97% identity of aa residues
(Fig. 2A). The phylogenic analysis suggested that PAP21 could
have common ancestor and, moreover, human and mouse
PAP21 seem to be more closer evolutionally to that of African
clawed frog and worms, rather than insects such as fruit ﬂy and
mosquito (Fig. 2B).
Furthermore, to evaluate tissue expression pattern of
hPAP21 (C2orf7), Northern blot analysis was performed using
Human Multiple Tissue Northern Blot membrane (Clontech).
The data indicated that the gene was highly expressed in
skeletal muscle, heart and liver, as well as moderate in kidney,
only with single transcript of about 1.1 kb (Fig. 3).
3.2. Expression and secretion of hPAP21
To deﬁne whether hPAP21 could be secreted into extracel-
lular medium, recombinant plasmid pcDNA3.1-hPAP21-Myc
was transiently and stably transfected into CHO cells. Inter-
estingly, the c-Myc-His tagged hPAP21 fusion protein was
detected by antibody against c-Myc in both CM and CL via
Western blotting assay after aﬃnity puriﬁcation by Ni2þ resin
(Fig. 4), demonstrating that hPAP21 (C2orf7) indeed encodes
a secretory protein. However, two main bands, approximately
30 kDa, of hPAP21 fusion protein in CM, as shown in Fig. 4
(indicated by ‘a’ and ‘b’ arrows), were signiﬁcantly larger than
those in CL (Fig. 4, indicated by ‘c’ arrow), implying that post-
translational modiﬁcation could be pivotal process during the
secretion of hPAP21.
3.3. N-glycosylation state of hPAP21
PROSITE program prediction suggested that the aa residues
121–124 (NDSF) and 171–174 (NVTS) of hPAP21 could have
two potential N-glycosylation modiﬁcation sites. To deﬁne theFig. 3. Tissue expression pattern of hPAP21 (C2orf7). HumanMultiple
Tissue Northern Blot membranes (Clontech) were hybridized with
hPAP21 (C2orf7) cDNA probe.b-Actin was used as control.issue, PNG F and Endo H, which can cleave N-linked oligo-
saccharide structures from Asn intact, as well as chitobiose core
of high mannose and some hybrid oligosaccharides from N-Fig. 5. The eﬀect of N-glycosylation on the secretion of hPAP21.
(A) The eﬀect of tunicamycin, an inhibitor of N-glycosylation, on
biosynthesis and secretion of wild-type hPAP21. The CHO cells
transfected with wild-type hPAP21 were treated with (+) or without
()) tunicamycin for 24 h, and then protein derived from CL and CM
was analyzed, respectively, through Western blotting assay. TM, tu-
nicamycin. (B) The eﬀect of potential glycosylation sites on the se-
cretion of hPAP21. The mutants were constructed via site-directed
mutagenesis assay and transfected into CHO cells, whereas the plasmid
containing wild type hPAP21 was used as control. (C) The evaluation
of secreted eﬃciency between wild-type and mutants of hPAP21. The
percentage of secreted protein was determined by density ratio of se-
creted forms to both intracellular and extracellular forms through
densitometry scans on Western blotting. The experiments were re-
peated three times. Data values and error bars showed the means and
SD, respectively.
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experiments. Interestingly, both intercellular and extracellular
forms of hPAP21 were sensitive to PNG F as all larger bands
were cleaved to similar minor bands of about 26 kDa, indicating
that there are N-glycosylation modiﬁcations indeed, whatever
intercellular or extracellular forms (Fig. 4). However, only in-
tracellular form displayed the sensitivity as endoglycosidase H
(Endo H) treatment, whereas the two larger bands, indicated by
‘a’ and ‘b’ arrows in Fig. 4, of extracellular forms seem to be
resistant to the enzyme although the minor extracellular form
was cleaved by Endo H. The data suggested that the glycosyla-
tion modiﬁcations could be diﬀerent between intercellular and
extracellular forms although all hPAP21 forms were modiﬁed
through N-glycosylation. Also, the facts, which major forms of
extracellular hPAP21were only sensitive to PNGF, not to Endo
H, whereas single intracellular form may be cleaved by both
enzymes, implied that, unlike intracellular form with high
mannose glycosylation, theN-glycosylation of secreted hPAP21
was mainly synthesized via heterogeneous complex-type oligo-
saccharide chains, which could take place in Golgi apparatus,
not in endoplasmic reticulum [12].3.4. Eﬀect of N-glycosylation on secretion
To determine whether glycosylation was necessary for
hPAP21 secretion, the CHO cells with exogenous hPAP21
were treated for 24 h by tunicamycin, an inhibitor of N-gly-
cosylation. Interestingly, the hPAP21 of CM was not detected
by Western blotting assay after tunicamycin treatment,
whereas N-glycosylation of the protein in cells was simulta-
neously inhibited, as the protein band was minished to
approximately 26 kDa, the same as the size after PNG F
treatment (Fig. 5A), supporting that N-glycosylation was
required for the secretion of hPAP21.Fig. 6. The subcellular localization of hPAP21. The subcellular localization o
with secondary antibodies conjugated to Cy5 (red), whereas pEYFP-Golgi (
merged images showed the co-localized positions (yellow), The slides were o
hormone (hGH) and p28 genes were used as positive and negative controls,Furthermore, to evaluate the eﬀect of the two potential
N-glycosylation sites, 121–124 (NDSF) and 171–174 (NVTS),
on the secretion of hPAP21, three mutants, Asn121Gln,
Asn171Gln and both, were constructed by site-directed mu-
tagenesis assay, respectively, and then the recombinant plas-
mids containing wild-type and mutants of hPAP21 were
transiently transfected into CHO cells. The Western blotting
assay showed that the recombinant mutant 2 (Asn171Gln) and
mutant 3 (Asn121Gln and Asn171Gln) could not be signiﬁ-
cantly glycosylated, by contrast, the mutant 1 (Asn121Gln),
like wild-type, was glycosylated in extracellular forms
(Fig. 5B), suggesting that N-glycosylation of Asn171, not
Asn121, was required for the secretory hPAP21. However, it is
pointed out that the mutated proteins were still secreted into
CM, although the secretion of mutant 2 and mutant 3 was
downregulated about 40% as compared with wild-type
(Fig. 5C), implying that the N-glycosylation of Asn171 was
important, albeit not necessary, for the secretion.
3.5. Secretion pathway of hPAP21
Generally, as known, the secretory protein was transported
from ER to Golgi apparatus and trans-Golgi network
(TGN), and then delivered outside. To determine whether
the secretion of hPAP21 did indeed go through Golgi ap-
paratus, the plasmid pEYFP-Golgi (Clontech) containing the
membrane-anchoring signal peptide that targets the EYFP
fusion protein to the trans-medial region of the Golgi ap-
paratus was employed for co-transfection into CHO cells
with pcDNA3.1-hPAP21-Myc. The view under the confocal
microscope showed that, like growth factor as positive con-
trol, hPAP21 and EYFP were co-localized in TGN as the
merged images from both proteins emit yellow light (Fig. 6),
suggesting that the secretion of hPAP21 was a classical or
ER/Golgi-dependent pathway.f hPAP21 in CHO cells was visualized by anti-c-Myc (9E10), together
green) also was simultaneously co-transfected into the same cells. The
bserved under a laser-scanning confocal microscope. Human growth
respectively.
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hPAP21, encoded by the hypothetical gene C2orf7, was
conﬁrmed to be expressed in skeletal muscle, heart and liver by
this study albeit the functions of the protein need to be further
investigated. Interestingly, hPAP21 has a PA domain in its
middle, except for signal peptide in its N-terminus. PA domain
exists in many diﬀerent types of proteases, including the M28
metallopeptidase families that belonged to MH clan [15], al-
though the function of PA domain in these proteases was still
largely unknown. Herein, phylogenetic analysis showed that
PAP21 was evolutionally conservative as several orthologs
from worms to mouse occur, as shown in Fig. 2, implying that
the PAP21 might be important for cell behaviors. Recently, the
homologs of Caenorhabditis elegans, XF509 (T07F12.2)
(NP_508831), had been studied by DNA microarray [16] and
systematic RNAi functional analyses [17]. However, the
knock-down of the gene via RNAi assay did not signiﬁcantly
lead the abnormal phenotype, including morphology, maternal
phenotype and embryonic lethality. In this study, we also did
not ﬁnd the eﬀect of hPAP21 on cell cycle and cell proliferation
(data not shown).
Interestingly, hPAP21 may be secreted into CM as predicted
by many software programs, and the molecular weight of the
protein in medium was about 2 kDa bigger than that in the
intracellular counterpart. Similar phenomena were observed in
mature hTPP I due to the diverse oligosaccharide structures
caused by lysosomal glycosidases in lysosomes [18]. Herein,
our data indicated that the intracellular form of hPAP21 was
mainly modiﬁed by high mannose-type glycans, whereas the
secreted hPAP21 was primarily modiﬁed by complex-type ol-
igosaccharide chains, similar to human a-galactosidase A
overexpressed in CHO cells [19,20]. As known, the complex-
type oligosaccharide chains were mainly synthesized in Golgi
apparatus. We showed here that the intracellular hPAP21
might be partially localized in Golgi apparatus as predicted
(Fig. 6).
Segregation is thought to occur in the trans-Golgi network
(TGN) and is mediated by sorting signals embedded within
the protein structure such as N- and O-linked glycans,
speciﬁc transmembrane domains or glycosylphosphatidyli-
nositol (GPI) anchors, and cytoplasmic domain determinants
[21]. N-glycans can mediate protein exit Golgi apparatus to
the cell surface in polarized and non-polarized cells [22],
playing a structural role or acting as sorting signals as the
existence of lectin receptors [23]. Herein, tunicamycin, an
inhibitor of N-glycosylation, can markedly decrease the
biosynthesis and secretion of hPAP21 into the medium,
similar to the eﬀect of tunicamycin on meprin A [10], im-
plying that N-glycans were important for the secretion of
hPAP21. Moreover, Asn171 of the protein could be crucial
site for N-glycosylation based on the site-directed muta-
genesis experiments (Fig. 5). However, hPAP21 without the
glycosylation of Asn171 was still secreted into the medium
although with less eﬃciency, suggesting that other unknown
glycoproteins or processes were necessary for the secretion
of hPAP21, rather than only the N-glycosylation of hPAP21
itself. The N-glycans might prefer a conformational re-
quirement to a sorting signal, by stabilizing the folded forms
or improving the interaction with its receptor. Moreover, the
complex-type glycans for the secretion of certain glycopro-
teins would be more eﬃcient than the high mannose type.Such an indirect structural role of N-glycans has been
shown in the intracellular transport of VSVG protein [24]
and the interaction of CD2 with its receptor [25].
It is estimated that 90% proteins with the sequence Asn-X-
Ser/Thr are glycosylated [26], and the glycosylation of Asn-X-
Thr sequons is reduced when the sequon is within 60 residues
of the C-terminus of the protein [27,28]. However, our data
here showed that only the 171–174 aa (NVTS) of hPAP21 was
glycosylated, not in the 121–124 aa (NDSF) of the protein,
although 171–174 aa (NVTS) was within 18 residues of the
C-terminus, implying that the glycosylated eﬃciency of Asn-
Xaa-Thr sequons of hPAP21 could be independent of distance
from the C-terminus, similar to membrane dipeptidase [29].
To summarize, we here characterized the expression pat-
tern, secretion and glycosylation of hPAP21, encoded by the
hypothetical gene C2orf7. Moreover, Endo H and PNG F
were employed to evaluate the eﬀect of glycosylation types
on secretion of hPAP21. Interestingly, the extracellular
forms were primarily sensitive to PNG F, not Endo H,
implying that complex N-glycosylation could be required for
the secretion of hPAP21. Furthermore, N-glycosylation of
Asn171 was conﬁrmed as potential crucial process for the
secretory protein via site-directed mutagenesis assay. How-
ever, although the data will be helpful to the understanding
of molecular functions of hPAP21, we will further investi-
gate the eﬀect of the secretory protein on cell communica-
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